ValiRx PLC Conclusion of Hokkaido Evaluation Agreement (9761C)
16 Giugno 2023 - 8:00AM
UK Regulatory
TIDMVAL
RNS Number : 9761C
ValiRx PLC
16 June 2023
ValiRx PLC
("ValiRx" or the "Company")
Conclusion of Hokkaido Evaluation Agreement
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health,
announces the conclusion of the evaluation agreement with Hokkaido
University, as announced on 16 December 2021 and extended on 6
December 2022.
Under this agreement, ValiRx committed to conducting a range of
experiments following initial confirmation of the synthetic route
and analysis. After overcoming initial challenges in synthesis and
purification of the peptide, testing has been conducted on the
product. However, the profile of the product has been found to be
unsuitable for further development at this stage and the evaluation
will now cease. As agreed, the data generated under the evaluation
agreement will be provided to the originating academics at Hokkaido
University to enable them to optimise the molecular profile. There
is no further commitment to the project by ValiRx.
Dr Suzy Dilly, CEO of ValiRx commented: "Although it's
disappointing not to be able to progress this project further, this
highlights the importance of our process of evaluating academic
projects prior to full in-licensing. In addition to returning the
data to Hokkaido, we have made recommendations for further work,
and we will be following the scientific progress of project with
interest."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 as it forms part of
UK Domestic Law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR"). The Directors of the Company take responsibility
for this announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
--------------------------
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
--------------------------
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397
8900
Russell Kerr/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
--------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
--------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFMSIMEDSEIM
(END) Dow Jones Newswires
June 16, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mag 2023 a Mag 2024